• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ZUCLOPENTHIXOL Drug Record

  • Summary
  • Interactions
  • Claims
  • ZUCLOPENTHIXOL chembl:CHEMBL53904

    Alternate Names:

    ZUCLOPENTHIXOL
    CLOPENTHIXOL CIS(Z)-FORM
    CLOPENTHIXOL
    ZUCLOPENTIXOL
    CIS-CLOPENTHIXOL
    CIS(Z)-CLOFLUPENTIXOL
    NSC 64087
    CISORDINOL®
    ACUPHASE®
    NSC169185
    (Z)-4-(3-(2-CHLOROTHIOXANTHEN-9-YLIDENE)PROPYL)-1-PIPERAZINEETHANOL
    ZUCLOPENTHIXOLUM
    CLOPIXOL®
    chembl:CHEMBL53904
    pubchem.compound:5311507
    chemidplus:53772-83-1
    drugbank:01624
    rxcui:114176

    Drug Info:

    FDA Approval 1962
    Drug Class small molecule
    Drug Indications Antipsychotic Agents
    Year of Approval 1962
    Drug Class antipsychotic agents
    (2 More Sources)

    Publications:

    Manzaneque et al., An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice., Methods Find Exp Clin Pharmacol
    Lublin et al., 1991, Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia., Eur Neuropsychopharmacol
    Nyberg et al., 1995, Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans., Int Clin Psychopharmacol
    Gareri et al., 2003, Conventional and atypical antipsychotics in the elderly : a review., Clin Drug Investig
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Dahl ML et al., 1991, Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans., Acta Psychiatr Scand
    Jaanson P et al., 2002, Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype., Psychopharmacology (Berl)
  • ZUCLOPENTHIXOL   DRD5

    Interaction Score: 3.8

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10222441 1822319


    Sources:
    TdgClinicalTrial TEND

  • ZUCLOPENTHIXOL   DRD2

    Interaction Score: 0.52

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8748043 17535043 11752352 1822319


    Sources:
    TdgClinicalTrial TEND TTD

  • ZUCLOPENTHIXOL   DRD1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10222441 1822319


    Sources:
    TdgClinicalTrial TEND

  • ZUCLOPENTHIXOL   CYP2D6

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1927573 12107620


    Sources:
    PharmGKB

  • ZUCLOPENTHIXOL   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: ZUCLOPENTHIXOL

    • Version: 01-August-2011

    Alternate Names:
    ZUCLOPENTHIXOL Primary Drug Name

    Drug Info:
    Drug Class antipsychotic agents
    Year of Approval 1962

    Publications:

  • TdgClinicalTrial: ZUCLOPENTHIXOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antipsychotic Agents
    Drug Class small molecule
    FDA Approval 1962

    Publications:

  • PharmGKB: zuclopenthixol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Jaanson P et al., 2002, Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype., Psychopharmacology (Berl)
    Dahl ML et al., 1991, Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans., Acta Psychiatr Scand

  • DTC: ZUCLOPENTHIXOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL87385 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Zuclopenthixol

    • Version: 2020.06.01

    Alternate Names:
    D0I8LU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL53904

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21